Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79,376,583
-
Total 13F shares
-
35,197,329
-
Share change
-
+207,098
-
Total reported value
-
$744,225,550
-
Price per share
-
$21.15
-
Number of holders
-
92
-
Value change
-
+$3,822,622
-
Number of buys
-
35
-
Number of sells
-
47
Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q4 2021
As of 31 Dec 2021,
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,197,329 shares.
The largest 10 holders included
Skorpios Trust, JANUS HENDERSON GROUP PLC, ALKEON CAPITAL MANAGEMENT LLC, Atlas Venture Life Science Advisors, LLC, venBio Partners LLC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, GOLDMAN SACHS GROUP INC, Point72 Asset Management, L.P., and Redmile Group, LLC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.